Over the past few days, you’ve likely seen a number of my articles discussing just how important “game-changing” stocks are to your portfolio. (Feel free to visit my archive to read anything you missed).

In fact, we put together an entire webcast discussing four of my favorite game-changers. The event was held yesterday, but if you weren’t one of the 5,000 people who signed up to attend, I have some good news. To let everyone in on the four game-changing stocks I’ve found, StreetAuthority archived the webcast. You can view it immediately by following this link.

But there’s something else…

I wanted to talk a little more in-depth about one of the game-changing stocks that I’ve found. I’m really excited about this company, and while I discuss in the webcast, I think it deserves a little more attention.

The story behind this stock starts with some recently published research findings from the American Cancer Society. These findings deal with a serious type of cancer — the second leading cause of cancer-related death, in fact. It’s colon cancer. And one in 19 people will be diagnosed with this disease in their lifetimes.

The American Cancer Society’s findings basically emphasize one thing about colon cancer. It simply must be detected early for the patient to have the best chance of survival. Despite the evidence supporting the effectiveness of colorectal screening and the availability of various screening tests, half of the U.S. population over 50 has not been tested.

The reality is that people don’t get this procedure because it’s a horrible test. It’s risky, it hurts, it’s unpleasant to think about, it takes and ruins a whole day. 

But it doesn’t have to. Just as technology changed the movie business and the music industry and every other thing in the world, so too will emerging medical technology change the colonoscopy.

This change is coming with virtual colonoscopies. This test uses a CT scanner to take a picture from outside the body, and is 90% accurate. Plus there is no need for a general anesthetic, which some older patients can’t tolerate, and there is no risk of perforation of the bowel, which can be life threatening.

The company at the vanguard of this major shift in diagnostic protocols is iCAD (Nasdaq: ICAD), which is already a major participant in the industry and a leader in the space, though the name is probably far more familiar to radiologists that it is to patients. Right now, the federal government is poised to approve iCAD’s virtual colonoscopy tool, which will open up a whole new market.

To tell you a little more about iCAD and its future, I put together the audio chat below. Simply click play below to watch.  (Please make sure your computer speakers are turned on and that your volume is high enough for you to hear the audio.)

I hope that you’re seeing some of the potential behind iCAD. I think it could be a big winner over the next several years. But remember, it’s just one of the four game-changing stocks that I identified for my webcast. I’d invite you to listen to the archived presentation (it’s free). Simply visit this link to listen immediately.